CONDITION

Idiopathic amyloidosis

Idiopathic amyloidosis is amyloid protein buildup for which no underlying cause has been identified.

WHAT IT IS
Abnormal amyloid protein deposits without an identified cause

BODY SYSTEM
Several organs, especially heart, kidneys, and nerves

MAIN SYMPTOMS
Fatigue, swelling, breathlessness, numbness

WHAT CAUSES IT
Unknown after evaluation

HOW IT IS DIAGNOSED
Tissue biopsy and amyloid protein typing

MAIN TREATMENT
Amyloid-type treatment and organ support

CAN IT BE CURED?
Sometimes - localized deposits may be removable

IS IT AN EMERGENCY?
Sometimes - severe breathlessness or fainting

LONG-TERM OUTLOOK
Shaped by amyloid type and organ damage

Overview

Amyloidosis is a group of conditions in which abnormal proteins fold into a shape called amyloid. Amyloid can collect in tissues and interfere with how an organ works.

"Idiopathic" means that no cause has been identified after evaluation. It does not name a specific amyloid protein. Modern testing can often identify the protein involved, so a diagnosis may later be changed from idiopathic amyloidosis to a more precise type.

Amyloid may be limited to one area, called localized amyloidosis, or affect several organs, called systemic amyloidosis. The heart, kidneys, nerves, liver, digestive tract, skin, lungs, and soft tissues can be involved.

Identifying the amyloid type matters because treatments are very different. A treatment that

helps one type may not help another. Some older medical records use "primary" or "idiopathic" amyloidosis for what is now usually called AL amyloidosis, but these terms are not automatically interchangeable.

Symptoms

Symptoms depend on where amyloid has collected. Early symptoms can be mild and may resemble those of more common conditions. Some people with localized deposits have few symptoms.

Possible symptoms include:

Heart involvement can make the heart muscle thick and stiff. This limits how well it fills with blood and can lead to fluid buildup. Kidney involvement often allows protein to leak into the urine. Nerve involvement may affect sensation, digestion, bladder control, sweating, or sexual function.

None of these symptoms confirms amyloidosis. Testing is needed because many other conditions can cause the same problems.

- Tiredness, weakness, or unintended weight loss
- Breathlessness, ankle swelling, faintness, or an irregular heartbeat
- Foamy urine or swelling around the legs and eyes
- Numbness, tingling, burning pain, or weakness in the hands and feet
- Dizziness when standing because of a drop in blood pressure
- Diarrhoea, constipation, feeling full quickly, or difficulty swallowing
- Easy bruising, including bruising around the eyes
- Carpal tunnel symptoms, such as hand numbness at night
- An enlarged tongue, although this is uncommon and mainly linked with AL amyloidosis

Causes and risk factors

Amyloid forms when certain proteins misfold and join together in insoluble fibres. The original protein determines the amyloidosis type.

In idiopathic amyloidosis, the source has not been found. This may mean the deposits are truly isolated, or that the protein type has not yet been identified. Expert review and newer

laboratory methods can sometimes provide a more specific diagnosis.

Recognized forms of amyloidosis include:

Risk patterns differ between types. Some become more likely with age. Others are associated with plasma cell disorders, chronic inflammatory conditions, long-lasting infections, or inherited genetic changes.

Amyloidosis is not contagious. There is no evidence that ordinary diet, stress, or everyday activities cause idiopathic amyloidosis.

- AL amyloidosis , caused by abnormal antibody fragments called light chains made by bone marrow plasma cells
- AA amyloidosis , linked with long-term inflammation from another condition
- ATTR amyloidosis , caused by the transthyretin protein and related either to ageing or an inherited gene variant
- Localized amyloidosis , in which deposits form in one place, such as the skin, bladder, airway, or eye

Diagnosis

Diagnosis has two connected goals: confirming that amyloid is present and identifying the protein that formed it.

A small tissue sample, called a biopsy, may be taken from abdominal fat, bone marrow, or an affected organ. The sample is stained with Congo red dye. Under specialized light, amyloid has a characteristic appearance.

Finding amyloid is not enough on its own. The protein should also be typed. Mass spectrometry, which identifies proteins by their molecular pattern, is often used when available. Antibody-based testing may also be used.

Blood and urine tests may look for abnormal light chains. These include serum free light-chain testing and immunofixation, a method that detects abnormal antibody proteins. Kidney and liver tests help show whether organs are affected.

Depending on your symptoms, assessment may also include:

A nuclear medicine heart scan can support a diagnosis of ATTR heart amyloidosis in a carefully defined situation. Doctors must first check for abnormal light chains because AL amyloidosis can produce confusing scan results.

A specialist amyloidosis centre may review biopsy samples or earlier test results when the

type remains unclear.

- An electrocardiogram and heart ultrasound
- Heart blood markers, such as troponin and NT-proBNP
- Heart magnetic resonance imaging
- Urine testing for protein
- Nerve tests
- Genetic testing when an inherited form is possible

Treatment and management

Treatment depends on whether the deposits are localized or systemic, which amyloid protein is present, and how much organ injury has occurred. Treatment is usually not started solely from the word "idiopathic" without efforts to determine the type.

Localized amyloid deposits may only need monitoring if they are not causing problems. Deposits that block an airway, affect vision, cause bleeding, or interfere with another structure may sometimes be removed or treated locally. They can return after treatment.

For systemic amyloidosis, treatment aims to reduce production of the protein that forms new deposits. Examples include plasma-cell-directed treatment for AL amyloidosis, control of the inflammatory condition in AA amyloidosis, and transthyretin-targeted treatment for certain forms of ATTR amyloidosis. These treatments are not interchangeable.

Supportive treatment can reduce the effects on affected organs. It may include treatment for fluid retention, abnormal heart rhythms, low blood pressure, nerve pain, digestive symptoms, or kidney failure. Dialysis, a pacemaker, or an organ transplant may be considered in selected situations.

People with heart amyloidosis can respond differently to medicines commonly used for other heart conditions. Medication changes should therefore be supervised by clinicians familiar with the condition. Do not stop prescribed medicine because of general information about amyloidosis.

Follow-up usually includes blood and urine tests, symptom review, and repeat assessment of affected organs. The results help show whether protein production is controlled and whether organ function is stable.

Complications

Complications reflect the organs involved. Systemic amyloidosis may cause heart failure, abnormal heart rhythms, severe drops in blood pressure, kidney failure, nerve damage, poor nutrition, or liver enlargement.

Heart involvement is especially important because it can affect circulation and the heart's electrical system. Kidney damage may lead to major protein loss, swelling, and the need for dialysis.

Treatment can reduce further amyloid formation, but existing organ damage may recover slowly or remain. Earlier identification of the amyloid type usually allows more appropriate treatment and monitoring.

Prevention

Idiopathic amyloidosis usually cannot be prevented because its cause is unknown.

Inherited amyloidosis also cannot be prevented by lifestyle changes. Genetic counselling can help relatives understand testing and monitoring options when an inherited type is confirmed.

When amyloidosis is linked with long-term inflammation, effective control of the underlying condition may reduce the chance of further AA amyloid formation. This does not guarantee prevention. There is no specific food, supplement, or exercise plan known to prevent idiopathic amyloid deposits.

Living with it and what to expect

The course over months and years is different for localized and systemic amyloidosis. Localized deposits may remain stable for long periods, although symptoms or deposits can recur after local treatment.

Systemic amyloidosis can progress if the amyloid-forming protein continues to be produced. Effective treatment may slow or stop new deposits. Organ function can then stabilize or improve, but improvement may take months and may be incomplete.

Some forms can return after a good response, so long-term monitoring is common. Follow-up may track abnormal proteins, heart markers, kidney function, urine protein, blood pressure, weight, and symptoms.

Your outlook cannot be estimated from the word "idiopathic" alone. It is influenced by the protein involved, the organs affected, how advanced the damage is, and the response to

treatment. Obtaining a precise type is one of the most useful steps for understanding what to expect.

Many people continue work, family life, travel, and suitable physical activity, with adjustments for fatigue, nerve symptoms, blood pressure changes, or organ problems. Your care team can advise on activity and fluid or salt intake based on your heart and kidney function.

When to get medical help

Arrange a routine medical appointment if you develop persistent unexplained swelling, foamy urine, breathlessness, numbness, weight loss, easy bruising, or dizziness when standing. These symptoms have many possible causes, but they deserve assessment if they continue.

If you already have amyloidosis, contact your care team promptly for a clear increase in swelling, rapidly worsening breathlessness, new palpitations, reduced urine output, repeated dizziness, or difficulty keeping down food and fluids. These changes may need earlier review rather than waiting for a scheduled appointment.

Seek emergency help for:

These symptoms do not necessarily mean amyloidosis has worsened, but they can signal a serious heart, circulation, or neurological problem.

- Severe difficulty breathing
- Chest pain that does not settle
- Fainting or collapse
- A very fast or irregular heartbeat with weakness or breathlessness
- Sudden facial drooping, arm weakness, or trouble speaking

Common questions

Is idiopathic amyloidosis the same as AL amyloidosis?

Not necessarily. Older sources sometimes used "primary" or "idiopathic" amyloidosis for AL amyloidosis. Today, AL refers specifically to deposits made from antibody light chains. Protein typing is needed before the terms can be linked.

Is amyloidosis a type of cancer?

Amyloidosis itself is not cancer. AL amyloidosis is caused by an abnormal group of plasma cells in the bone marrow and is related to certain blood cancers, but many people with AL

amyloidosis do not have multiple myeloma. Other amyloid types are unrelated to cancer.

Can amyloid deposits go away?

Localized deposits can sometimes be removed. In systemic amyloidosis, treatment mainly stops or reduces production of new amyloid-forming protein. Existing deposits may gradually decrease in some people, but organ recovery is often slow and cannot be guaranteed.

Is idiopathic amyloidosis inherited?

The term idiopathic means no cause has been identified, not that the condition is inherited. Some specific types, particularly hereditary ATTR amyloidosis, are caused by gene variants. Genetic testing may be recommended when the protein type, symptoms, or family history suggests this.

Is there a special amyloidosis diet?

There is no diet that removes amyloid. Dietary advice is based on the organs affected. For example, someone with fluid retention or kidney problems may receive specific advice about salt, fluids, protein, or potassium. Restricting these without individual guidance can be unhelpful.

How long can someone live with amyloidosis?

There is no single answer. Outlook differs greatly between localized and systemic forms and between amyloid proteins. Heart involvement, kidney function, stage at diagnosis, and treatment response are important. A precise amyloid type and organ assessment provide more useful information than the idiopathic label alone.

Sources

- National Health Service. Amyloidosis
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis nomenclature committee. Amyloid . 2020;27(4):217-222
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. The Lancet . 2016;387(10038):2641-2654 01274-X)
- Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers . 2018;4:38
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation . 2016;133(24):2404-2412



- Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. Journal of the American College of Cardiology . 2023;81(11):1076-1126